Last 12 months
Inside the activity.
1 purchase rows · 14 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 1 |
| Dec 2025 | 0 | 5 |
| Jan 2026 | 0 | 1 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 1 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 2 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 2 |
| Aug 2026 | 0 | 1 |
| Sep 2026 | 0 | 2 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 27, 2022 Filed Aug 30, 2022 01:00 UTC |
Tross Stuart AChief People & Workpl Officer
|
Tax withholdingCommon Stock, $.01 Par Value | 14,178 | $3.73 | $52,883.94 |
DisclosureSEC source: 0001209191-22-047942 · doc4.xml · nonDerivative · entry 1 Tross Stuart A · CIK 0001589641 · Chief People & Workpl Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 816,472 F1 · kind: Shares withheld to satisfy the tax liability incident to the vesting of previously reported restricted stock units. Read SEC document |
| August 22, 2022 Filed Aug 24, 2022 01:00 UTC |
Galindo AlejandroEVP Endocrine Business Unit
|
SaleCommon Stock, $0.01 Par Value | 15 | $3.84 | $57.60 |
DisclosureSEC source: 0001209191-22-047280 · doc4.xml · nonDerivative · entry 2 Galindo Alejandro · CIK 0001821447 · EVP Endocrine Business Unit 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 777,075 Read SEC document |
| August 22, 2022 Filed Aug 24, 2022 01:00 UTC |
Galindo AlejandroEVP Endocrine Business Unit
|
SaleCommon Stock, $0.01 Par Value | 4,600 | $3.85 | $17,713.22 |
DisclosureSEC source: 0001209191-22-047280 · doc4.xml · nonDerivative · entry 1 Galindo Alejandro · CIK 0001821447 · EVP Endocrine Business Unit 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 777,090 Read SEC document |
| July 31, 2022 Filed Aug 1, 2022 10:00 UTC |
Binder Steven B.Chief Financial Officer
|
PurchaseCommon Stock, $0.01 Par Value | 791 | $2.93 | $2,317.63 |
DisclosureSEC source: 0001209191-22-043573 · doc4.xml · nonDerivative · entry 1 Binder Steven B. · CIK 0001712601 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 728,997 F1 · kind: The reporting person purchased shares through the Company's Employee Stock Purchase Plan effective July 31, 2022. Read SEC document |
| July 31, 2022 Filed Aug 1, 2022 10:00 UTC |
Castagna MichaelDirector · Chief Executive Officer
|
PurchaseCommon Stock, $0.01 Par Value | 3,147 | $2.93 | $9,220.71 |
DisclosureSEC source: 0001209191-22-043575 · doc4.xml · nonDerivative · entry 1 Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,084,486 F1 · kind: The reporting person purchased shares through the Company's Employee Stock Purchase Plan effective July 31, 2022. Read SEC document |
| July 31, 2022 Filed Aug 1, 2022 10:00 UTC |
Tross Stuart AChief People & Workpl Officer
|
PurchaseCommon Stock, $0.01 Par Value | 4,581 | $2.93 | $13,422.33 |
DisclosureSEC source: 0001209191-22-043572 · doc4.xml · nonDerivative · entry 1 Tross Stuart A · CIK 0001589641 · Chief People & Workpl Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 830,650 F1 · kind: The reporting person purchased shares through the Company's Employee Stock Purchase Plan effective July 31, 2022. Read SEC document |
| July 31, 2022 Filed Aug 1, 2022 10:00 UTC |
Galindo AlejandroEVP Endocrine Business Unit
|
PurchaseCommon Stock, $0.01 Par Value | 5,000 | $2.93 | $14,650.00 |
DisclosureSEC source: 0001209191-22-043574 · doc4.xml · nonDerivative · entry 1 Galindo Alejandro · CIK 0001821447 · EVP Endocrine Business Unit 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 781,690 F1 · kind: The reporting person purchased shares through the Company's Employee Stock Purchase Plan effective July 31, 2022 representing the maximum allowable under the Plan for this period. Read SEC document |
| July 31, 2022 Filed Aug 25, 2022 01:01 UTC Amendment |
Castagna MichaelDirector · Chief Executive Officer
|
GrantCommon Stock, $0.01 Par Value | 3,147 | $2.93 | $9,220.71 |
DisclosureSEC source: 0001209191-22-047431 · doc4a.xml · nonDerivative · entry 1 Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,084,486 F1 · kind: This Form 4 is being amended to correct the transaction code. The securities were purchased through the Company's Employee Stock Purchase Plan effective July 31, 2022. Read SEC document |
| July 31, 2022 Filed Aug 25, 2022 01:01 UTC Amendment |
Tross Stuart AChief People & Workpl Officer
|
GrantCommon Stock, $0.01 Par Value | 4,581 | $2.93 | $13,422.33 |
DisclosureSEC source: 0001209191-22-047429 · doc4a.xml · nonDerivative · entry 1 Tross Stuart A · CIK 0001589641 · Chief People & Workpl Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 830,650 F1 · kind: This Form 4 is being amended to correct the transaction code. The securities were purchased through the Company's Employee Stock Purchase Plan effective July 31, 2022. Read SEC document |
| July 31, 2022 Filed Aug 25, 2022 01:01 UTC Amendment |
Binder Steven B.Chief Financial Officer
|
GrantCommon Stock, $0.01 Par Value | 791 | $2.93 | $2,317.63 |
DisclosureSEC source: 0001209191-22-047430 · doc4a.xml · nonDerivative · entry 1 Binder Steven B. · CIK 0001712601 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 728,997 F1 · kind: This Form 4 is being amended to correct the transaction code. The securities were purchased through the Company's Employee Stock Purchase Plan effective July 31, 2022. Read SEC document |
| July 31, 2022 Filed Aug 25, 2022 01:00 UTC Amendment |
Galindo AlejandroEVP Endocrine Business Unit
|
GrantCommon Stock, $0.01 Par Value | 5,000 | $2.93 | $14,650.00 |
DisclosureSEC source: 0001209191-22-047423 · doc4a.xml · nonDerivative · entry 1 Galindo Alejandro · CIK 0001821447 · EVP Endocrine Business Unit 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 781,690 F1 · kind: This Form 4 is being amended to correct the transaction code. The securities were purchased through the Company's Employee Stock Purchase Plan effective July 31, 2022. Read SEC document |
| May 18, 2022 Filed May 21, 2022 00:00 UTC |
Galindo AlejandroEVP Endocrine Business Unit
|
Tax withholdingCommon Stock, $.01 Par Value | 4,789 | $3.19 | $15,276.91 |
DisclosureSEC source: 0001209191-22-031202 · doc4.xml · nonDerivative · entry 1 Galindo Alejandro · CIK 0001821447 · EVP Endocrine Business Unit 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 771,901 F1 · kind: Shares withheld to satisfy the tax liability incident to the vesting of previously reported restricted stock units. Read SEC document |
| May 18, 2022 Filed May 21, 2022 00:01 UTC |
Castagna MichaelDirector · Chief Executive Officer
|
Tax withholdingCommon Stock, $.01 Par Value | 16,434 | $3.19 | $52,424.46 |
DisclosureSEC source: 0001209191-22-031205 · doc4.xml · nonDerivative · entry 1 Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,081,339 F1 · kind: Shares withheld to satisfy the tax liability incident to the vesting of previously reported restricted stock units. Read SEC document |
| May 18, 2022 Filed May 21, 2022 00:00 UTC |
Kocinsky JosephChief Technology Officer
|
Tax withholdingCommon Stock, $.01 Par Value | 5,383 | $3.19 | $17,171.77 |
DisclosureSEC source: 0001209191-22-031204 · doc4.xml · nonDerivative · entry 1 Kocinsky Joseph · CIK 0001655595 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 758,046 F1 · kind: Shares withheld to satisfy the tax liability incident to the vesting of previously reported restricted stock units. Read SEC document |
| May 18, 2022 Filed May 21, 2022 00:00 UTC |
Binder Steven B.Chief Financial Officer
|
Tax withholdingCommon Stock, $.01 Par Value | 5,972 | $3.19 | $19,050.68 |
DisclosureSEC source: 0001209191-22-031200 · doc4.xml · nonDerivative · entry 1 Binder Steven B. · CIK 0001712601 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 728,206 F1 · kind: Shares withheld to satisfy the tax liability incident to the vesting of previously reported restricted stock units. Read SEC document |
| May 18, 2022 Filed May 21, 2022 00:00 UTC |
Tross Stuart AChief People & Workpl Officer
|
Tax withholdingCommon Stock, $.01 Par Value | 5,941 | $3.19 | $18,951.79 |
DisclosureSEC source: 0001209191-22-031201 · doc4.xml · nonDerivative · entry 1 Tross Stuart A · CIK 0001589641 · Chief People & Workpl Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 826,069 F1 · kind: Shares withheld to satisfy the tax liability incident to the vesting of previously reported restricted stock units. Read SEC document |
| May 18, 2022 Filed May 21, 2022 00:00 UTC |
Thomson DavidEVP Genl Counsel & Secretary
|
Tax withholdingCommon Stock, $.01 Par Value | 6,001 | $3.19 | $19,143.19 |
DisclosureSEC source: 0001209191-22-031199 · doc4.xml · nonDerivative · entry 1 Thomson David · CIK 0001297976 · EVP Genl Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 747,213 F1 · kind: Shares withheld to satisfy the tax liability incident to the vesting of previously reported restricted stock units. Read SEC document |
| May 18, 2022 Filed May 26, 2022 00:00 UTC Amendment |
Galindo AlejandroEVP Endocrine Business Unit
|
OtherCommon Stock, $.01 Par Value | 4,789 | $3.19 | $15,276.91 |
DisclosureSEC source: 0001209191-22-031996 · doc4a.xml · nonDerivative · entry 1 Galindo Alejandro · CIK 0001821447 · EVP Endocrine Business Unit 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 776,690 F1 · kind: This report corrects total amount of securities beneficially owned as no shares were withheld to satisfy the tax liability incident on 5/18/2022 for the vesting of previously reported restricted stock units. Read SEC document |
| May 10, 2022 Filed May 13, 2022 00:01 UTC |
Castagna MichaelDirector · Chief Executive Officer
|
GrantRestricted Stock Unit | 311,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-028680 · doc4.xml · nonDerivative · entry 2 Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,097,773 F3 · shares: The restricted stock unit will vest on May 10, 2025 provided that the closing price of MannKind common stock on such vesting date is not less than the closing price on May 10, 2022. The number of shares delivered on the vesting date, as a percentage of the target specified in Box 4 above, is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from May 10, 2022 until May 10, 2025 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above. Read SEC document |
| May 10, 2022 Filed May 13, 2022 00:01 UTC |
Castagna MichaelDirector · Chief Executive Officer
|
GrantRestricted Stock Unit | 254,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-028680 · doc4.xml · nonDerivative · entry 1 Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,786,773 F1 · shares: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F2 · shares: Acquired pursuant to a Restricted Stock Unit Award: 25% vest on each year annivesary of the vesting determination date and 25% each anniversary thereafter; shares shall fully vest on the fourth year anniversary of the vesting determination date. Read SEC document |
| May 10, 2022 Filed May 13, 2022 00:01 UTC |
Galindo AlejandroEVP Endocrine Business Unit
|
GrantRestricted Stock Unit | 110,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-028679 · doc4.xml · nonDerivative · entry 2 Galindo Alejandro · CIK 0001821447 · EVP Endocrine Business Unit 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 776,690 F3 · shares: The restricted stock unit will vest on May 10, 2025 provided that the closing price of MannKind common stock on such vesting date is not less than the closing price on May 10, 2022. The number of shares delivered on the vesting date, as a percentage of the target specified in Box 4 above, is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from May 10, 2022 until May 10, 2025 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above. Read SEC document |
| May 10, 2022 Filed May 13, 2022 00:01 UTC |
Galindo AlejandroEVP Endocrine Business Unit
|
GrantRestricted Stock Unit | 90,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-028679 · doc4.xml · nonDerivative · entry 1 Galindo Alejandro · CIK 0001821447 · EVP Endocrine Business Unit 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 666,690 F1 · shares: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F2 · shares: Acquired pursuant to a Restricted Stock Unit Award: 25% vest on each year annivesary of the vesting determination date and 25% each anniversary thereafter; shares shall fully vest on the fourth year anniversary of the vesting determination date. Read SEC document |
| May 10, 2022 Filed May 13, 2022 00:01 UTC |
MUNDKUR CHRISTINEDirector
|
GrantRestricted Stock Unit · Derivative | 45,045 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-028678 · doc4.xml · derivative · entry 1 MUNDKUR CHRISTINE · CIK 0001237264 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,045 Underlying: Common Stock · 45,045 shares Expires 2032-05-10 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F2 · derivative.exercise_date: Annual Equity Award: Restricted stock unit shall vest immediately, but the shares shall not be delivered until there is a separation of service, such as through resignation or retirement from the Board or his or her death. Read SEC document |
| May 10, 2022 Filed May 13, 2022 00:01 UTC |
Thomson DavidEVP Genl Counsel & Secretary
|
GrantRestricted Stock Unit | 110,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-028677 · doc4.xml · nonDerivative · entry 2 Thomson David · CIK 0001297976 · EVP Genl Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 753,214 F3 · shares: The restricted stock unit will vest on May 10, 2025 provided that the closing price of MannKind common stock on such vesting date is not less than the closing price on May 10, 2022. The number of shares delivered on the vesting date, as a percentage of the target specified in Box 4 above, is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from May 10, 2022 until May 10, 2025 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above. Read SEC document |
| May 10, 2022 Filed May 13, 2022 00:01 UTC |
Thomson DavidEVP Genl Counsel & Secretary
|
GrantRestricted Stock Unit | 90,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-028677 · doc4.xml · nonDerivative · entry 1 Thomson David · CIK 0001297976 · EVP Genl Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 643,214 F1 · shares: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F2 · shares: Acquired pursuant to a Restricted Stock Unit Award: 25% vest on each year annivesary of the vesting determination date and 25% each anniversary thereafter; shares shall fully vest on the fourth year anniversary of the vesting determination date. Read SEC document |
| May 10, 2022 Filed May 13, 2022 00:00 UTC |
Grancio JenniferDirector
|
GrantRestricted Stock Unit · Derivative | 45,045 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-028676 · doc4.xml · derivative · entry 1 Grancio Jennifer · CIK 0001807888 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,045 Underlying: Common Stock · 45,045 shares Expires 2032-05-10 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F2 · derivative.exercise_date: Annual Equity Award: Restricted stock unit shall vest immediately, but the shares shall not be delivered until there is a separation of service, such as through resignation or retirement from the Board or his or her death. Read SEC document |
| May 10, 2022 Filed May 13, 2022 00:00 UTC |
Tross Stuart AChief People & Workpl Officer
|
GrantRestricted Stock Unit | 110,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-028675 · doc4.xml · nonDerivative · entry 2 Tross Stuart A · CIK 0001589641 · Chief People & Workpl Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 832,010 F3 · shares: The restricted stock unit will vest on May 10, 2025 provided that the closing price of MannKind common stock on such vesting date is not less than the closing price on May 10, 2022. The number of shares delivered on the vesting date, as a percentage of the target specified in Box 4 above, is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from May 10, 2022 until May 10, 2025 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above. Read SEC document |
| May 10, 2022 Filed May 13, 2022 00:00 UTC |
Tross Stuart AChief People & Workpl Officer
|
GrantRestricted Stock Unit | 90,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-028675 · doc4.xml · nonDerivative · entry 1 Tross Stuart A · CIK 0001589641 · Chief People & Workpl Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 722,010 F1 · shares: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F2 · shares: Acquired pursuant to a Restricted Stock Unit Award: 25% vest on each year annivesary of the vesting determination date and 25% each anniversary thereafter; shares shall fully vest on the fourth year anniversary of the vesting determination date. Read SEC document |
| May 10, 2022 Filed May 13, 2022 00:00 UTC |
Consiglio Ronald JDirector
|
GrantRestricted Stock Unit · Derivative | 45,045 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-028674 · doc4.xml · derivative · entry 1 CONSIGLIO RONALD J · CIK 0001232088 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,045 Underlying: Common Stock · 45,045 shares Expires 2032-05-10 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F2 · derivative.exercise_date: Annual Equity Award: Restricted stock unit shall vest immediately, but the shares shall not be delivered until there is a separation of service, such as through resignation or retirement from the Board or his or her death. Read SEC document |
| May 10, 2022 Filed May 13, 2022 00:00 UTC |
Kocinsky JosephChief Technology Officer
|
GrantRestricted Stock Unit | 110,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-028673 · doc4.xml · nonDerivative · entry 2 Kocinsky Joseph · CIK 0001655595 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 763,429 F3 · shares: The restricted stock unit will vest on May 10, 2025 provided that the closing price of MannKind common stock on such vesting date is not less than the closing price on May 10, 2022. The number of shares delivered on the vesting date, as a percentage of the target specified in Box 4 above, is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from May 10, 2022 until May 10, 2025 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above. Read SEC document |
| May 10, 2022 Filed May 13, 2022 00:00 UTC |
Kocinsky JosephChief Technology Officer
|
GrantRestricted Stock Unit | 90,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-028673 · doc4.xml · nonDerivative · entry 1 Kocinsky Joseph · CIK 0001655595 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 653,429 F1 · shares: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F2 · shares: Acquired pursuant to a Restricted Stock Unit Award: 25% vest on each year annivesary of the vesting determination date and 25% each anniversary thereafter; shares shall fully vest on the fourth year anniversary of the vesting determination date. Read SEC document |
| May 10, 2022 Filed May 13, 2022 00:00 UTC |
Shannon James SamuelDirector
|
GrantRestricted Stock Unit · Derivative | 45,045 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-028672 · doc4.xml · derivative · entry 1 Shannon James Samuel · CIK 0001485417 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,045 Underlying: Common Stock · 45,045 shares Expires 2032-05-10 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F2 · derivative.exercise_date: Annual Equity Award: Restricted stock unit shall vest immediately, but the shares shall not be delivered until there is a separation of service, such as through resignation or retirement from the Board or his or her death. Read SEC document |
| May 10, 2022 Filed May 13, 2022 00:00 UTC |
Binder Steven B.Chief Financial Officer
|
GrantRestricted Stock Unit | 110,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-028671 · doc4.xml · nonDerivative · entry 2 Binder Steven B. · CIK 0001712601 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 734,178 F3 · shares: The restricted stock unit will vest on May 10, 2025 provided that the closing price of MannKind common stock on such vesting date is not less than the closing price on May 10, 2022. The number of shares delivered on the vesting date, as a percentage of the target specified in Box 4 above, is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from May 10, 2022 until May 10, 2025 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above. Read SEC document |
| May 10, 2022 Filed May 13, 2022 00:00 UTC |
Binder Steven B.Chief Financial Officer
|
GrantRestricted Stock Unit | 90,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-028671 · doc4.xml · nonDerivative · entry 1 Binder Steven B. · CIK 0001712601 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 624,178 F1 · shares: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F2 · shares: Acquired pursuant to a Restricted Stock Unit Award: 25% vest on each year annivesary of the vesting determination date and 25% each anniversary thereafter; shares shall fully vest on the fourth year anniversary of the vesting determination date. Read SEC document |
| May 10, 2022 Filed May 13, 2022 00:00 UTC |
KRESA KENTDirector
|
GrantRestricted Stock Unit · Derivative | 45,045 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-028670 · doc4.xml · derivative · entry 1 KRESA KENT · CIK 0001197571 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,045 Underlying: Common Stock · 45,045 shares Expires 2032-05-10 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F2 · derivative.exercise_date: Annual Equity Award: Restricted stock unit shall vest immediately, but the shares shall not be delivered until there is a separation of service, such as through resignation or retirement from the Board or his or her death. Read SEC document |
| May 10, 2022 Filed May 13, 2022 00:00 UTC |
Friedman Michael ADirector
|
GrantRestricted Stock Unit · Derivative | 45,045 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-028669 · doc4.xml · derivative · entry 1 Friedman Michael A · CIK 0001298083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,045 Underlying: Common Stock · 45,045 shares Expires 2032-05-10 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F2 · derivative.exercise_date: Annual Equity Award: Restricted stock unit shall vest immediately, but the shares shall not be delivered until there is a separation of service, such as through resignation or retirement from the Board or his or her death. Read SEC document |
| May 10, 2022 Filed May 13, 2022 00:00 UTC |
Kay SabrinaDirector
|
GrantRestricted Stock Unit · Derivative | 45,045 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-028668 · doc4.xml · derivative · entry 1 Kay Sabrina · CIK 0001835895 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,045 Underlying: Common Stock · 45,045 shares Expires 2032-05-10 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F2 · derivative.exercise_date: Annual Equity Award: Restricted stock unit shall vest immediately, but the shares shall not be delivered until there is a separation of service, such as through resignation or retirement from the Board or his or her death. Read SEC document |
| May 10, 2022 Filed May 13, 2022 00:00 UTC |
HOOPER ANTHONY CDirector
|
GrantRestricted Stock Unit · Derivative | 45,045 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-028667 · doc4.xml · derivative · entry 1 HOOPER ANTHONY C · CIK 0001277244 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,045 Underlying: Common Stock · 45,045 shares Expires 2032-05-10 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F2 · derivative.exercise_date: Annual Equity Award: Restricted stock unit shall vest immediately, but the shares shall not be delivered until there is a separation of service, such as through resignation or retirement from the Board or his or her death. Read SEC document |
| February 28, 2022 Filed Mar 1, 2022 22:01 UTC |
Galindo AlejandroChief Commercial Officer
|
PurchaseCommon Stock,$.01 par value | 36,900 | $2.71 | $99,999.00 |
DisclosureSEC source: 0001209191-22-014102 · doc4.xml · nonDerivative · entry 1 Galindo Alejandro · CIK 0001821447 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 576,690 Read SEC document |
| February 28, 2022 Filed Mar 1, 2022 22:00 UTC |
HOOPER ANTHONY CDirector
|
PurchaseCommon Stock,$.01 par value | 40,000 | $2.71 | $108,400.00 |
DisclosureSEC source: 0001209191-22-014097 · doc4.xml · nonDerivative · entry 1 HOOPER ANTHONY C · CIK 0001277244 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 338,394 Read SEC document |
| February 28, 2022 Filed Mar 1, 2022 22:00 UTC |
MUNDKUR CHRISTINEDirector
|
PurchaseCommon Stock,$.01 par value | 27,675 | $2.71 | $74,999.25 |
DisclosureSEC source: 0001209191-22-014096 · doc4.xml · nonDerivative · entry 1 MUNDKUR CHRISTINE · CIK 0001237264 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 254,493 Read SEC document |
| February 28, 2022 Filed Mar 1, 2022 22:00 UTC |
Tross Stuart AChief People & Workpl Officer
|
PurchaseCommon Stock,$.01 par value | 9,225 | $2.71 | $24,999.75 |
DisclosureSEC source: 0001209191-22-014095 · doc4.xml · nonDerivative · entry 1 Tross Stuart A · CIK 0001589641 · Chief People & Workpl Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 632,010 Read SEC document |
| February 28, 2022 Filed Mar 1, 2022 22:00 UTC |
Castagna MichaelDirector · Chief Executive Officer
|
PurchaseCommon Stock,$.01 par value | 27,675 | $2.71 | $74,999.25 |
DisclosureSEC source: 0001209191-22-014094 · doc4.xml · nonDerivative · entry 1 Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,532,773 Read SEC document |
| February 28, 2022 Filed Mar 1, 2022 22:00 UTC |
Grancio JenniferDirector
|
PurchaseCommon Stock,$.01 par value | 110,701 | $2.71 | $299,999.71 |
DisclosureSEC source: 0001209191-22-014093 · doc4.xml · nonDerivative · entry 1 Grancio Jennifer · CIK 0001807888 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 244,815 Read SEC document |
| February 28, 2022 Filed Aug 25, 2022 01:00 UTC Amendment |
Tross Stuart AChief People & Workpl Officer
|
GrantCommon Stock,$.01 par value | 9,225 | $2.71 | $24,999.75 |
DisclosureSEC source: 0001209191-22-047426 · doc4a.xml · nonDerivative · entry 1 Tross Stuart A · CIK 0001589641 · Chief People & Workpl Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 632,010 F1 · kind: This Form 4 is being amended to correct the transaction code. The securities were purchased through the Issuer's Market Price Stock Purchase Plan effective February 28, 2022. The purchase was approved by the Company's Board of Directors. Read SEC document |
| February 28, 2022 Filed Aug 25, 2022 01:00 UTC Amendment |
Galindo AlejandroEVP Endocrine Business Unit
|
GrantCommon Stock,$.01 par value | 36,900 | $2.71 | $99,999.00 |
DisclosureSEC source: 0001209191-22-047428 · doc4a.xml · nonDerivative · entry 1 Galindo Alejandro · CIK 0001821447 · EVP Endocrine Business Unit 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 576,690 F1 · kind: This Form 4 is being amended to correct the transaction code. The securities were purchased through the Issuer's Market Price Stock Purchase Plan effective February 28, 2022. The purchase was approved by the Company's Board of Directors. Read SEC document |
| February 28, 2022 Filed Aug 25, 2022 01:00 UTC Amendment |
Castagna MichaelDirector · Chief Executive Officer
|
GrantCommon Stock,$.01 par value | 27,675 | $2.71 | $74,999.25 |
DisclosureSEC source: 0001209191-22-047425 · doc4a.xml · nonDerivative · entry 1 Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,532,773 F1 · kind: This Form 4 is being amended to correct the transaction code. The securities were purchased through the Issuer's Market Price Stock Purchase Plan effective February 28, 2022. The purchase was approved by the Company's Board of Directors. Read SEC document |
| January 31, 2022 Filed Feb 2, 2022 22:00 UTC |
Galindo AlejandroChief Commercial Officer
|
PurchaseCommon Stock, $0.01 Par Value | 2,334 | $3.17 | $7,398.78 |
DisclosureSEC source: 0001209191-22-006415 · doc4.xml · nonDerivative · entry 1 Galindo Alejandro · CIK 0001821447 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 540,320 F1 · kind: The reporting person purchased shares through the Company's Employee Stock Purchase Plan effective January 31, 2022. Read SEC document |
| January 31, 2022 Filed Feb 2, 2022 22:00 UTC |
Binder Steven B.Chief Financial Officer
|
PurchaseCommon Stock, $0.01 Par Value | 711 | $3.17 | $2,253.87 |
DisclosureSEC source: 0001209191-22-006418 · doc4.xml · nonDerivative · entry 1 Binder Steven B. · CIK 0001712601 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 534,178 F1 · kind: The reporting person purchased shares through the Company's Employee Stock Purchase Plan effective January 31, 2022. Read SEC document |
| January 31, 2022 Filed Feb 2, 2022 22:00 UTC |
Castagna MichaelDirector · Chief Executive Officer
|
PurchaseCommon Stock, $0.01 Par Value | 2,334 | $3.17 | $7,398.78 |
DisclosureSEC source: 0001209191-22-006414 · doc4.xml · nonDerivative · entry 1 Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,505,628 F1 · kind: The reporting person purchased shares through the Company's Employee Stock Purchase Plan effective January 31, 2022. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.